Can I inject Plegridy intramuscularly instead of subcutaneously?
We have received several questions regarding the ability to inject Plegridy intramuscularly instead of subcutaneously. During the phase I development of Plegridy, Biogen determined that the subcutaneous and intramuscular route of injection, using the same product for both routes of administration, provides a similar pharmacokinetic and pharmacodynamic profile. This suggests that both routes of administration could be used with Plegridy in people with MS. However, Biogen has not done any clinical testing of intramuscular Plegridy with humans.
Given this information it may be reasonable for you and your doctor to consider a trial of intramuscular Plegridy, only if you are a patient who experiences significant and prolonged injection site reactions with subcutaneous Plegridy but you otherwise tolerate and benefit from this treatment.
This is an off label route of administration and would require your doctor to agree with this route of administration.
Revere (Rip) Kinkel MD
Director of the Multiple Sclerosis Program
Director of Hillcrest Neurology
Professor of Clinical Neurosciences
University of California San Diego